Articles from AAVantgarde

MILAN, April 23, 2026 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company pioneering next-generation gene therapies for inherited retinal diseases (IRDs) has today announced its participation in the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2026, taking place May 3-7 in Denver (CO).

MILAN, April 21, 2026 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company pioneering next-generation gene therapies for inherited retinal diseases (IRDs) has today announced the successful completion of patient recruitment in its STELLA natural history study.

MILAN, April 01, 2026 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company pioneering therapies for inherited retinal diseases (IRDs) focused on large gene delivery via its two proprietary Adeno-Associated Viral (AAV) vector platforms, today announced the appointment of Philip Lao as Senior Vice President of Business Development. Mr. Lao joins the Company’s leadership team and will report to Dr. Natalia Misciattelli, Chief Executive Officer.

This milestone marks significant progress in the first-in-human evaluation of AAVantgarde’s dual-AAV gene therapy designed to address the underlying cause of vision loss in patients with USH1B

LONDON and MILAN, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company pioneering therapies for inherited retinal diseases (IRDs), today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12-15, 2026 in San Francisco, California.

LONDON and MILAN, Nov. 03, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, biotechnology company pioneering therapies for inherited retinal diseases (IRDs), today announced the successful closing of a $141 million (€122 million) Series B financing round.

MILAN, Oct. 07, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced three presentations at the European Society of Gene & Cell Therapy 32nd Annual Meeting (ESGCT), to be held October 7-10 in Seville (Spain).

MILAN, Oct. 02, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted AAVB-039, the company’s investigational gene therapy for the treatment of Stargardt disease secondary to biallelic mutation in ABCA4, Orphan Drug Designation (ODD). The company has also received Clinical Trial Authorisation (CTA) approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA).

MILAN, Sept. 05, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases, today announced the presentation of updated clinical data from the LUCE-1 study at the 25th European Society of Retina Specialists (EURETINA) Annual Congress (EURetina 2025), taking place in Paris 4-7 September 2025.

MILAN, Aug. 28, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases, today announced the presentation of updated LUCE-1 clinical data at the 25th European Society of Retina Specialists (EURETINA) Annual Congress (EURetina 2025), taking place in Paris 4-7 September 2025. AAVantgarde will also be presenting at the Ophthalmology Futures Forum (OFF) and EURetina Innovation Spotlight (EIS) events on the 3rd September in Paris.

MILAN, Aug. 12, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for AAVB-039, the company’s gene therapy program for Stargardt disease secondary to biallelic mutation in ABCA4. The Investigational New Drug (IND) application for AAVB-039 was cleared to proceed by the FDA. Stargardt disease is the most common inherited form of macular degeneration and a leading cause of vision loss in children and young adults. AAVB-039 addresses the underlying genetic cause of the disease by providing the full-length ABCA4 protein and has the potential to benefit all patients with ABCA4 mutations.

MILAN, July 15, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for AAVB-039, the company’s gene therapy program for Stargardt disease.

MILAN, May 12, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announces the presentation of two abstracts at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO), held May 4-8, 2025 in Salt Lake City (US).

MILAN, April 28, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announced the appointment of Mr. Rasmus Holm-Jorgesen as their Chief Financial Officer (CFO). Rasmus brings over 25 years of experience in strategy, finance and global operations within the biopharmaceutical industry to AAVantgarde and has joined the Company’s leadership team, reporting to Dr Natalia Misciattelli, Chief Executive Officer.